Additional data from Spark’s SPK-RPE65 phase 3 trial show gains in functional vision, light sensitivity

SPK-RPE65 resulted in a sustained difference in functional vision and light sensitivity between study subjects and controls, according to additional data from a phase 3 pivotal trial, Spark Therapeutics announced in a press release.SPK-RPE65 is the company’s lead product candidate for the treatment of RPE65-mediated inherited retinal dystrophies.